Aclaris Therapeutics Inc [ACRS] stock is trading at $1.32, down -1.49%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ACRS shares have gain 3.94% over the last week, with a monthly amount glided 11.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aclaris Therapeutics Inc [NASDAQ: ACRS] stock has seen the most recent analyst activity on January 22, 2024, when H.C. Wainwright downgraded its rating to a Neutral. Previously, William Blair downgraded its rating to Mkt Perform on November 13, 2023. On October 03, 2023, Evercore ISI initiated with a Outperform rating and assigned a price target of $22 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $29 on December 14, 2022. Goldman initiated its recommendation with a Buy and recommended $25 as its price target on December 01, 2022. BTIG Research started tracking with a Buy rating for this stock on October 06, 2022, and assigned it a price target of $32.
Aclaris Therapeutics Inc [ACRS] stock has fluctuated between $0.59 and $11.12 over the past year. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.32 at the most recent close of the market. An investor can expect a potential return of 1793.94% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
Aclaris Therapeutics Inc [NASDAQ:ACRS] reported sales of 31.12M for the trailing twelve months, which represents a drop of -5.14%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -2.61%, Pretax Profit Margin comes in at -2.49%, and Net Profit Margin reading is -2.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.49 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2833 points at the first support level, and at 1.2467 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3933, and for the 2nd resistance point, it is at 1.4667.
Ratios To Look Out For
For context, Aclaris Therapeutics Inc’s Current Ratio is 6.74. As well, the Quick Ratio is 6.74, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 3.02, the price to book ratio is 0.66.
Transactions by insiders
Recent insider trading involved Leonard Braden Michael, 10% Owner, that happened on Jul 05 ’24 when 0.12 million shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Jul 03 ’24 to buy 0.14 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 86092.0 shares on Jul 02 ’24.
